Scientists map out antiviral Drug's journey in tiny human trial
NCT ID NCT05050682
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study gave a single IV dose of the antiviral PF-07304814 to 5 healthy adults. Researchers measured how much of the drug ended up in urine and feces, and how it was processed in the blood. The goal was simply to understand the drug's breakdown and elimination, not to test if it works against any virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-07304814 (an antiviral drug given by IV)
- What this could lead to
- If successful, this study will help researchers understand how the body handles PF-07304814, which could support future trials for treating viral infections.
- What could go wrong
- This is a very small, early-phase study in healthy volunteers, not patients. It only looks at how the drug moves through the body, not whether it works against any disease. Results may not predict effectiveness or safety in sick people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit - Madison
Madison, Wisconsin, 53704, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test